Implantable system for cell growth control

Details Implantable system for cell growth control Implantable system for cell growth control

1996-03-18

1999-10-12

Buiz, Michael

Surgery

Controlled release therapeutic device or system

Implanted dynamic device or system

623 1, 623 11, A61K 922

Patent

active

059647450

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND

1. Field of the Invention
The invention relates to methods and apparatus for control of cell growth, including angiogenesis, in porous implants, produced from ceramics, of the low density type from the general family described in Banas, et al, Thermophysical and Mechanical Properties of the HTP Family of Rigid Ceramic Insulation Materials, AIAA 20th Thermophysics Conference, Jun. 19-21, 1985, Williamsburg, Va. (incorporated herein by reference), Creedon, et al., Strength and Composites, SAMPE Quarterly, October and (incorporated herein by reference), U.S. Pat. No. 4,148,962, issued to Leiser, et al. on April 1979 (incorporated herein by reference). As an example of the general family, a thermal insulation material is produced by Lockheed Missiles & Space Company, Inc. of Sunnyvale, Calif., having the following properties, according to what is believed to be an Occupational Health and Safety Administration Material Data Sheet of Feb. 28, 1989, as follows:


I. PRODUCT IDENTIFICATION

Trade name (as labeled): HTP (High Thermal Performance) Material Chemical names, common names: Thermal insulation material. Manufacturer's name: Lockheed Missiles & Space Company, Inc. Address: 1111 Lockheed Way, Sunnyvale, Calif. 94089


______________________________________ Emergency phone: (408) 742-7215 Refer questions to: (6 a.m.-5 p.m. PST) Lockheed Missiles & Space (408) 742-3536 Company, Inc. (Off Hours) Occupational Safety & Health Dept. Org/4720 - 8/106 Business phone: (408) 742-7215 Date prepared: 1/89 ______________________________________


______________________________________ II. HAZARDOUS INGREDIENTS Chemical Gas Exposure Limits in Air Percent AGGIH Names Numbers (by vt.) OSHA (PEL) (TLV) Other ______________________________________ Alu- 1344-28-1 10-15 5 mg/m.sup.3 /15 m 10 mg/m.sup.3 mina g/m.sup.3 (Total nui- Fiber (Respirable/ sance dust) Total dust) Silica 60676-86-0 50-90 5 mg/m.sup.3 /15 m 10 mg/m.sup.3 See Fiber g/m.sup.3 (Fibrous Health (Respirable/ Glass Effect Total dust) Silicon 409-21-2 1-3 5 mg/m.sup.3 /15 m 10 mg/m.sup.3 Carbide g/m.sup.3 (Total nui- (Respirable/ sance dust) Total dust) Boron 10-043-115 1-5 5 mg/m.sup.3 /15 m 10 mg/m.sup.3 Nitride g/m.sup.3 (Total nui- (Respirable/ sance dust) Total dust) ______________________________________ III. PHYSICAL PROPERTIES Vapor density (air = 1): NA Softening point or range, degrees F: 2876 Specific gravity: Varies Boiling point or range, degrees F: NA Solubility in water: Nil Vapor pressure, mmHg at 20 degrees c: NA Evaporation rate (butyl acetate = 1): NA Appearance and odor: Solid off-white blocks, no odor. ______________________________________


IV. FIRE AND EXPLOSION



V. HEALTH HAZARD INFORMATION
some congestion may occur.
Acute: Mechanical irritant to skin, eyes, and upper respiratory system.
Chronic: Results of studies on the effect of silica fiber exposure causing malignant and non-malignant respiratory disease in man are controversial. Studies on laboratory animals fall in to two categories: animals which breathed high concentrations showed no disease, while some exposed through artificial means (e.g., implantation) have developed cancer. Recent U.S. and European studies of almost 27,000 production workers (1930s to 1980s) found no significant increase in disease from fiber glass exposure. Even though the extensive human studies were judged inadequate for carcinogenicity, IARC has classified glass wool as possibly carcinogenic for humans, based on the artificially exposed animal studies. Fibrous glass is not considered a carcinogen by NTP and OSHA. As a conservative approach in the absence of conclusive knowledge indicating otherwise, we recommend treating this material as if it is a potential carcinogen. Handling procedures such as HEPA vacuum and local exhaust ventilation should be used to minimize exposure. See Special Handling Procedures.
Periodic air monitoring is recommended. The NIOSH r

REFERENCES:
patent: 5024671 (1991-06-01), Tu et al.
patent: 5201728 (1993-04-01), Giampapa
"New Challenges in Biomaterials," Peppas et al., Science, vol. 263, Mar. 25, 1994, pp. 1715-1720.
"Tissue Engineering," Langer et al., Science, vol. 260, May 14, 1993, pp. 920-926.
"Tissue Engineering Using Cells and Synthetic Polymers," Mooney et al., Transplantation Reviews, vol. 7, No. 3 (Jul.), 1993;pp. 153-162.
"Stabilized polyglycolic acid fibre-based tubes for tissue engineering," Mooney et al., Biomaterials 1996, vol. 17, No. 2, pp. 115-124.
"Transport characterization of membranes for immunoisolation," Dionne et al., Biomaterials 1996, vol. 17, No. 3, pp. 257-266.
"Characterization of the formation of interfacially photopolymerized thin hydrogels in contact with arterial tissue," Lyman et al., Biomaterials 1996, vol. 17, No. 3, pp. 359-364.
"Biointeractive polymers and tissue engineered blood vessels," Greisler et al., Biomaterials 1996, vol. 17, No. 3, pp. 329-336.
"Kinetics of bone cell organization and mineralization on materials with patterned surface chemistry," Healy et al., Biomaterials 1996, vol. 17, No. 2, pp. 195-208.
"Conditions which promote mineralization at the bone-implant interface: a model in vitro study," Dee et al., Biomaterials 1996, vol. 17, No. 2, pp. 209-215.
"Role of material surfaces in regulating bone and cartilage cell response," Boyan et al., Biomaterials 1996, vol. 17, No. 2, pp. 137-146.
"Bone-Grafting Materials in Implant Dentistry," Misch et al., Implant Dentistry, vol. 2, No. 3, pp. 158-167.
"Anorganic Bovine Bone and Ceramic Analogs of Bone Mineral as Implants to Facilitate Bone Regeneration," Myron Spector, PhD, Clinics in Plastic Surgery, vol. 21, No. 3, Jul. 1994, pp. 437-444.
"Bioactive Factors and Biosynthetic Materials in Bone Grafting," Hollinger et al., Clinics in Plastic Surgery, vol. 21, No. 3, Jul. 1994, pp. 415-418.
"Tissue-Engineered Morphogenesis of Cartilage and Bone by Means of Cell Transplantation Using Synthetic Biodegradable Polymer Matrices," Vacanti et al., Clinics in Plastic Surgery, vol. 21, No. 3, Jul. 1994, pp., 445-462.
"Biomaterials in orthopaedic surgery: effects of different hydroxyapartites and demineralized bone matrix on proliferation rate and bone matrix synthesis by human osteoblasts," Zambonin et al., Biomaterials 1995, vol. 16, No. 5, pp. 397-402.
"Bone and Cartilage Reconstruction with Tissue Engineering Approaches," Vacanti, et al., Otolaryngologic Clinics of North America, vol. 27, No. 1, Feb. 1994, pp. 263-276.
"Osteogenesis in muscle with composite graft of hydroxyapatite and autogenous calvarial periosteum: a preliminary report," Kurashina et al., Biomaterials 1995, vol. 16, No. 2, pp. 119-123.
"Effect of Bioactive Glass Templates on Osteoblast Proliferation and In Vitro Synthesis of Bone-Like Tissue," Ducheyne et al., Journal of Cellular Biochemistry 56:162-167 (1994).
"Biotechnology and Bone Graft Substitutes," Kenley et al., Pharmaceutical Research, vol. 10, No. 10, 1993, pp. 1393-1401.
"Implantation of sepiolite-collagen complexes in surgically created rat calvaria defects," Herrera et al., Biomaterials 1995, vol. 16, No. 8, pp. 625-631.
"Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats," Marden et al., Journal of Biomedical Materials Research, vol. 28, 1127-1138 (1994).
"Facial Bone Healing and Bone Grafts," Paul N. Manson, MD, Clinics in Plastic Surgery, vol. 21, No. 3, Jul. 1994, pp. 331-348.
"The Effect of Osteogenin (a Bone Morphogenetic Protein) on the Formation of Bone in Orthotopic Segmental Defects in Rats," Stevenson et al., The Journal of Bone and Joint Surgery, vol. 76-A, No. 11, Nov. 1994, pp. 1676-1687.
"Histomorphometric Analysis of the Repair of a Segmental Diaphyseal Defect with Ceramic and Titanium Fibermetal Implants: Effects of Bone Marrow," Wolff et al., Journal of Orthopaedic Research, vol. 12, No. 3, 1994, pp. 439-446.
"Symbiosis of Biotechnology and Biomaterials: Applications in

Affiliated with

Also associated with

Rating

Implantable system for cell growth control does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Implantable system for cell growth control, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Implantable system for cell growth control will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-647357